Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Design and synthesis of 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-one derivatives as novel anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase
Novel 6,7-methylenedioxy-4-substituted phenylquinolin-2(1H)-onederivatives 12a–n were designed and prepared through an intramolecular cyclization reaction and evaluated for in vitro anticancer activity. Among the synthesized compounds, 6,7-methylenedioxy-4-(2,4-dimethoxyphenyl)quinolin-2(1H)-one (12e) displayed potent cytotoxicity against several different tumor cell lines at a sub-micromolar level
通过分子内环化反应设计和制备了新型 6,7-亚甲二氧基-4-取代的苯基喹啉-2(1 H )-one 衍生物12a – n,并评估了其体外抗癌活性。在合成的化合物中,6,7-亚甲二氧基-4-(2,4-二甲氧基苯基)喹啉-2(1 H )-one ( 12e ) 在亚微摩尔水平对几种不同的肿瘤细胞系显示出有效的细胞毒性。此外,荧光激活细胞分选 (FACS) 分析的结果表明12e诱导细胞周期停滞在 G2/M 期,伴随着 HL-60 和 H460 细胞的凋亡。Hoechst 染色和 caspase-3 激活证实了这一作用。由于其易于合成和显着的生物活性,4-苯基喹啉-2(1 H )-one 类似物 (4-PQs) 是基于喹啉支架的有前途的新型抗癌先导物。因此,化合物12e被鉴定为一种新的先导化合物,值得进一步优化和开发作为抗癌候选物。
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against <i>Mycobacterium tuberculosis</i>. Part II
identification of novel coumestan derivatives as Mycobacterium tuberculosis ( Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations observed (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies. Herein, we report a further structure-activity relationships exploration exploiting the available Pks13-TE X-ray co-crystal structure that resulted in the discovery of extremely potent coumestan
Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.